INTRODUCTION — Fragile X syndrome (FXS) is an X-linked disorder and the most common inherited cause of intellectual disability [1]. Both males and females can be affected.
The clinical features and diagnosis of FXS (previously called fragile X mental retardation syndrome, X-linked mental retardation and macro-orchidism, and Martin-Bell syndrome) in children and adolescents are discussed in this topic review. Prenatal screening and the management of FXS in children and adolescents are discussed separately. (See "Prenatal screening and diagnosis for fragile X syndrome" and "Fragile X syndrome: Management in children and adolescents".)
PATHOGENESIS — FXS is an X-linked disorder. It is caused by decreased or absent levels of fragile X mental retardation protein (FMRP) due to a loss-of-function mutation in the fragile X mental retardation 1 (FMR1) gene, located at Xq27.3 [2,3]. In more than 99 percent of cases, loss of function is caused by an unstable expansion of a trinucleotide (cytosine-guanine-guanine, CGG) repeat at the 5' untranslated region [4,5]. Deletions, point mutations, and missense mutation in FMR1 also may cause FXS but are rare [4,6,7].
There are two clinically significant levels of CGG expansion:
●Full mutation – Expansion of >200 repeats is known as full mutation and leads to methylation-coupled silencing of the FMR1 gene and absence of FMRP, causing the classical FXS phenotype. (See 'Full mutation in boys' below and 'Full mutation in girls' below.)
●Premutation – A smaller expansion of between approximately 50 to 55 and 200 repeats is known as premutation. The FMR1 gene remains transcriptionally active, FMRP is produced, and the classic FXS phenotype does not occur. However, a spectrum of clinical findings is associated with the premutation. Premutation alleles exhibit instability upon transmission, especially from a carrier mother, and may result in a full mutation in one or more generations [8-11]. (See 'Premutation' below.)
DNA methylation turns off gene activity, thus preventing gene transcription. Elongation of the CGG repeats allows hypermethylation of FMR1, resulting in impaired transcription and reduced production of the FMRP. Lower levels of FMRP appear to have a major impact upon the severity of the FXS phenotype. Individuals with nearly normal levels of FMRP may have mild or no symptoms, while those with very little or no normal FMRP may have more severe symptoms. (See "Principles of epigenetics", section on 'DNA methylation'.)
The genetics and molecular biology of FXS are discussed in detail separately [12]. (See "Prenatal screening and diagnosis for fragile X syndrome", section on 'Overview'.)
EPIDEMIOLOGY — FXS (MIM #300624) is the most frequent form of inherited intellectual disability, with a disease prevalence due to the full mutation of between 1 in 4000 and 1 in 7000 in males [1,4,13]. The prevalence of the full mutation in females, which has a variable clinical presentation, is approximately two-thirds to one-half of that in males [4,13]. However, this prevalence measure may be inappropriately low as females with a mild phenotype may go undiagnosed. The premutation rate is approximately 1 in 750 to 1 in 850 men and 1 in 250 to 1 in 300 in women [1,13-15]. FXS has been diagnosed in up to 3 percent of boys with significant neurodevelopmental disorders (eg, autism, nonsyndromic intellectual disability) [16].
CLINICAL FEATURES — The clinical features of FXS vary depending upon the mutation state (full mutation versus premutation), degree of methylation, sex, tissue variation/mosaicism, and possibly magnitude of the fragile X mental retardation protein (FMRP) deficit (table 1) [4,5,16-19]. Males with the full mutation are usually significantly affected. The degree of impairment varies widely in females with the full mutation.
Full mutation in boys — All males with the full mutation have manifestations of FXS, but there is a wide range of physical, cognitive, and behavioral features [20]. The physical features may be subtle. The classic presentation is a young boy with global developmental delay and typical behavioral characteristics, described below. Approximately 15 percent present with symptoms of attention deficit hyperactivity disorder (ADHD) or specific learning disability [21].
Physical features — The physical features of FXS in males vary depending upon age [16,22-26].
●Adolescents - The classic physical manifestations are more obvious in adolescents (picture 1):
•Long and narrow face with prominent forehead and chin (prognathism)
•Large ears
•Testicular enlargement (volume >25 mL after puberty) with normal testicular function
●Infants and young boys – Physical manifestations are subtle in infants and young boys. Nonetheless, some craniofacial and connective tissue findings may be present from a young age (picture 2). These include [16,20,24,27-29]:
•Relative macrocephaly (head circumference >50th percentile for age and sex) [4]
•Strabismus
•Pale blue irises
•Midface hypoplasia with sunken eyes
•Arched palate
•Mitral valve prolapse (seemingly benign)
•Joint hyperlaxity (particularly of the thumbs, fingers, and wrists)
•Hypotonia
•Doughy skin over the dorsum of hands
•Flexible flat feet
Testicular enlargement is usually not seen in boys under eight years of age [23,30].
Macrocephaly is related to underlying structural anomalies. Magnetic resonance imaging and quantitative morphometry demonstrate that individuals with an FMR1 gene full mutation have increased total brain volume, with relatively increased caudate nucleus, fourth ventricle, and hippocampal volumes and decreased cerebellar vermis volume [31-33]. In addition, boys with FXS have decreased lateral ventricle volume [31]. Caudate nucleus volume correlates with the methylation status of the FMR1 gene, and both caudate nucleus and lateral ventricular volumes correlate with intelligence quotient (IQ).
Cognitive function — Developmental delay (including delayed attainment of motor and language milestones), intellectual disability, and learning disabilities are the most salient clinical features of FXS [34]. In addition, cognitive level and adaptive behavior skills decline after early childhood, reflecting the slow acquisition of skills compared with other children of the same age rather than a regression of skills [20,35-39]. The decline occurs in all areas: quantitative skills, verbal reasoning, visual/abstract abilities, and short-term memory [37]. These observations highlight the importance of early intervention to facilitate cognitive abilities and adaptive behavior skills [20,38]. (See 'Diagnosis' below and "Fragile X syndrome: Management in children and adolescents".)
Boys with FXS typically sit alone at 10 months, walk at 20.6 months, and say their first clear words at 20 months (compared with approximately 7 months, 13 months, and 11 months, respectively, in typically developing children) [4].
Boys with FXS have delayed language development. Expressive language skills are achieved more slowly than receptive language skills, and the discrepancy between expressive and receptive skills increases with age [34,40]. Approximately 10 percent of boys with FXS are nonverbal [21].
Expressive language is often tangential (eg, responses or comments that do not relate to the topic of conversation) and perseverative, with inappropriate self-repetition, echolalia (involuntary parrot-like repetition), and pragmatic errors [20,34,41]. In contrast to individuals with autism, boys with FXS who often exhibit autistic-like features generally take appropriate turns during conversation [34].
Articulation is poor, and language is repetitive and characterized by short and fast utterances [42]. Cluttering is often present. Cluttering is a rapid, fluctuating rate of speech with repetitions of sounds, words, and phrases and occasional garbled, slurred, or disorganized speech.
Prepubertal boys and, in particular, preschool boys with FXS generally have higher IQs than adolescents and adults [42]. Adult males typically have an IQ in the moderate intellectual disability range, but intellectual disability ranges from mild to severe. (See "Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis", section on 'Severity classification'.)
Although individual strengths and weaknesses may vary from patient to patient, consistent strengths among boys with FXS include verbal skills (verbal reasoning, simple labeling, vocabulary, verbal comprehension) [20]. Consistent weaknesses include mathematics abilities, visuospatial abilities, attention and executive function (eg, the ability to organize information, plan ahead, problem solve), and visual-motor coordination [20,35,43-45].
Behavioral features — The behavioral phenotype of boys with FXS shares features with ADHD, anxiety, and autism spectrum disorder (eg, hyperactivity, inattention, gaze aversion, and stereotypic movements, such as hand flapping, hyperarousal, social anxiety, unusual speech patterns) [35,46-49]. (See "Autism spectrum disorder: Clinical features", section on 'Restricted and repetitive behavior, interests, and activities' and 'Autism' below and "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Core symptoms' and "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Clinical features'.)
Boys with FXS are more inattentive, overactive, and impulsive than boys with other types of intellectual disability [46]. These symptoms may be related to sensory hyperreactivity and lack of stimulus inhibition. They may lead to a diagnosis of ADHD. The ADHD-like symptoms tend to decline with age, but many adult males with FXS remain hyperactive. Treatment with stimulant medication may be beneficial [5]. (See "Fragile X syndrome: Management in children and adolescents", section on 'Hyperactivity and inattention'.)
Boys with FXS may have avoidant behaviors, particularly when their intellectual disability is severe [47]. They tend to avoid new situations and to move away from new objects [46]. However, they do not remain socially withdrawn or avoid familiar people.
Boys with FXS also may have anxiety symptoms (nervousness, obsessive-compulsive disorder-like obsessions and perseverations), mood instability, aggressive behavior, and self-injurious behavior [50-52].
Autism — It is estimated that 18 to 67 percent of males with FXS meet the criteria for autism spectrum disorder [47,53,54]. Boys with FXS and autism have greater impairments in cognitive skills, social interaction, academic achievement, language ability, and adaptive behavior than boys with FXS alone and are also more likely to have seizures [5,55-58]. (See "Autism spectrum disorder: Evaluation and diagnosis", section on 'Evaluation for associated conditions' and "Autism spectrum disorder: Clinical features".)
Seizures — Approximately 10 to 20 percent of boys with FXS develop seizures [59-61]. The risk of seizures is highest in childhood (peak incidence between six months and four years; mean age of onset two years) [5,60,61]. Most are simple or complex partial seizures, including benign childhood epilepsy with centrotemporal spikes (also known as benign rolandic epilepsy), although other types can occur. The seizures are relatively easy to control and often spontaneously remit during childhood [5]. (See "Benign (self-limited) focal epilepsies of childhood", section on 'Benign epilepsy with centrotemporal spikes' and "Fragile X syndrome: Management in children and adolescents", section on 'Seizures'.)
Additional associated findings — Children with FXS can have slow motor development and often present with hypotonia in infancy. Infants with hypotonia can have associated feeding problems, gastroesophageal reflux, and recurrent otitis. (See "Fragile X syndrome: Management in children and adolescents", section on 'Evaluation to determine extent of disease'.)
Strabismus, joint laxity, and mitral valve prolapse may also be present. Except for strabismus, these findings usually do not demand surgical intervention.
Prader-Willi phenotype — A subgroup of boys with FXS has a phenotype similar to that of Prader-Willi syndrome (PWS; ie, obesity and hyperphagia) but do not have the characteristic cytogenetic or methylation abnormalities at 15q11-13 [62-65]. Autism is more common in boys with FXS and the Prader-Willi phenotype than in boys with FXS without the Prader-Willi phenotype (54 versus approximately 30 percent) [65]. (See "Clinical features, diagnosis, and treatment of Prader-Willi syndrome" and "Epidemiology and genetics of Prader-Willi syndrome" and 'Autism' above.)
Full mutation in girls — The phenotype of full-mutation FXS in girls is much more variable than in boys because of individual differences in inactivation of the fragile X chromosome [20]. Approximately 50 percent of girls with a full fragile X mutation have normal intellect. The remaining 50 percent usually have milder features than boys, but the full spectrum of cognitive, behavioral, and physical findings may occur [16].
As many as 50 percent of females with the full mutation have some of the characteristic physical features (eg, prominent ears) [66]. Approximately 50 percent of women with the full mutation have IQs in the borderline or mild intellectual disability range [66-69]. Cognitive impairment appears to correlate with the activation ratio of the fragile X chromosome rather than the size of the amplification [70]. As in males with full-mutation FXS, cognitive function may decline after early childhood. (See "Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis".)
Many girls with the full mutation have associated behavioral or emotional problems [50,66,71]. They typically present with learning difficulties (especially in math), attention problems (or full ADHD), and shyness or social anxiety [21]. Deficits in visual-motor coordination, executive function (eg, the ability to organize information, plan ahead, problem solve), and language (including selective mutism) are common [21,72-74]. Girls with the full mutation are at risk for affective and schizophrenia spectrum disorders [50,75]. Autistic behaviors (eg, communication and social interaction deficits, stereotypies) are more commonly reported among 6- to 16-year-old girls with FXS than age- and IQ-matched controls [76]. Approximately 20 percent of females with FXS meet the criteria for autism spectrum disorder [47,53,54]. (See "Specific learning disabilities in children: Clinical features", section on 'Clinical features' and "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Core symptoms' and "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Clinical features' and "Autism spectrum disorder: Clinical features".)
Approximately 5 percent of girls with FXS develop seizures [59-61]. (See 'Seizures' above.)
Premutation — Individuals with fragile X premutation have between 55 and 200 cytosine-guanine-guanine (CGG) repeats. At this level, the FMR1 gene remains transcriptionally active, and the classic FXS phenotype does not occur. (See 'Pathogenesis' above.)
There are three potential areas of concern for individuals with fragile X premutations:
●Premature ovarian insufficiency (POI) in women, which is discussed separately (see "Clinical manifestations and diagnosis of spontaneous primary ovarian insufficiency (premature ovarian failure)")
●Fragile X-associated tremor-ataxia syndrome (FXTAS) later in life, which is discussed separately (see "The spinocerebellar ataxias", section on 'Fragile X-associated tremor/ataxia syndrome')
●Neurocognitive deficits [77]
In the past, fragile X premutation was not thought to affect cognitive function. However, there are reports of individuals with premutation and neurobehavioral manifestations, including cognitive and social skills deficits, anxiety, executive dysfunction, and autism [5,78-81]. Decreased FMRP levels have been detected in some of these individuals, suggesting a spectrum of clinical severity related to relative FMRP deficit [78,82].
The author's clinical practice has identified several boys with fragile X premutation and learning problems, developmental delay, or autistic features. This may reflect an ascertainment bias. However, they have identified four times more premutations in boys younger than 16 years with developmental problems who were referred for FMR1 gene testing than would be expected based upon the known prevalence of the premutation in males (unpublished data). Larger and more longitudinal studies are necessary, but these data provide additional evidence that fragile X premutations may affect neurocognitive and behavioral functioning in children.
DIAGNOSIS — It is important to make the diagnosis of FXS as early as possible so that appropriate interventions (eg, speech and language therapy, special education support, genetic counseling) can be initiated [21]. Surveys of parents of children diagnosed with FXS indicate a significant delay between the onset of their concerns (average age approximately 12 months) and the diagnosis of FXS (average age 35 to 37 months). Approximately one-fourth of families had a second child with a full mutation before the first child was diagnosed [83,84]. The diagnosis is based upon the phenotypic presentation as well as the genotype.
Indications for testing — In the absence of a family history of FXS, the diagnosis of FXS requires clinical suspicion based upon cognitive, developmental, or behavioral concerns, as described above. The diagnosis is confirmed by molecular testing. (See 'Clinical features' above and 'FMR1 DNA analysis' below.)
Child with suspected FXS — The American Academy of Pediatrics Committee on Genetics recommends testing for FXS (see 'FMR1 DNA analysis' below) in children with any of the following, particularly when associated with physical and behavioral characteristics of FXS or a relative with undiagnosed intellectual disability [85]:
●Developmental delay
●Borderline intellectual abilities or intellectual disability
●Diagnosis of autism without a specific etiology
Although the yield of molecular testing in such individuals is low [86], early diagnosis is important for timely genetic counseling. (See "Prenatal screening and diagnosis for fragile X syndrome", section on 'Candidates for screening' and "Autism spectrum disorder: Evaluation and diagnosis", section on 'Genetic testing' and "Intellectual disability in children: Evaluation for a cause", section on 'Testing for fragile X syndrome'.)
Adult with suspected FXS — Genetic testing should also be offered to the following patients, after an appropriate explanation of the test and its potential implications for the patient and their family [85]:
●Females with primary ovarian insufficiency (POI)
●Patients over 50 years of age with progressive cerebellar ataxia and intention tremor
●Adults with typical physical features and intellectual disability without a specific etiology
Testing for mutations in the FMR1 gene is also suggested for individuals who had cytogenetic testing in the past if the results of the testing and the clinical/behavioral phenotype are inconsistent [87].
FXS suspected due to family history — Family history findings that are suggestive of FXS include [16]:
●Cognitive effects – Intellectual disability, developmental delay, learning disabilities, specific problems with mathematics
●Speech delay or unusual speech pattern
●Autism spectrum disorder or autistic-like behaviors
●Attention deficit or attention deficit hyperactivity disorder (ADHD)
●Dysmorphic features – Macrocephaly, large ears, long face, broad forehead, prominent jaw, strabismus, large testicles
●Features of loose connective tissue – Hyperextensible joints, flat feet, hypotonia, mitral valve prolapse, hernias
●Neurologic symptoms – Seizures, late-onset progressive tremor, ataxia, difficulty walking, balance problems, short-term memory loss, loss of sensation in limbs
●Mental illness/personality disorders – Depression, schizophrenia, bipolar disorder, obsessive-compulsive disorder, schizoaffective disorder, schizoid personality
●Behavioral problems – Impulsiveness, anger outbursts, violent behavior, solitary behavior, counseling or medication for behavioral difficulties
●Shyness, social anxiety, excessive worrying, counseling or medication for emotional difficulties
●Premature menopause, fertility problems
Molecular testing is warranted if several of these features are present in combination in a symptomatic individual (eg, a child with developmental delay and/or behavioral problems, a woman with premature menopause, or an older male with ataxia) or in someone with a strong family history. Genetic counseling and genetic testing are also suggested for at-risk family members of patients with FXS, even if they are asymptomatic.
FMR1 DNA analysis — The diagnosis of FXS is based upon detection of an alteration in the fragile X mental retardation 1 (FMR1) gene [4]. Measuring the number of repeats in the CGG segment of FMR1 is used to identify persons with premutation or full mutation, in addition to those who have a normal or intermediate number of repeats. Testing methods and indications for prenatal screening are discussed separately. In addition, a detailed description of molecular genetic tests and the testing strategy for FMR1-related disorders is available through the Genetic Testing Registry (GTR). (See "Prenatal screening and diagnosis for fragile X syndrome", section on 'Preconception and prenatal screening' and "Prenatal screening and diagnosis for fragile X syndrome", section on 'Laboratory testing'.)
DIFFERENTIAL DIAGNOSIS — The differential diagnosis of FXS includes [4,88,89]:
●Autism spectrum disorder – Although children with FXS often have autistic behaviors and may have comorbid autism, absence of other clinical features of FXS suggests the isolated diagnosis of autism. (See "Autism spectrum disorder: Clinical features", section on 'Terminology'.)
●Attention deficit hyperactivity disorder (ADHD) – FXS is unlikely in the child with ADHD and normal intelligence. (See "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Clinical features' and "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis", section on 'Core symptoms'.)
●Other causes of intellectual disability or developmental delay, including (see "Intellectual disability (ID) in children: Clinical features, evaluation, and diagnosis"):
•Fragile XE syndrome (FRAXE) – FRAXE, which is extremely rare, is characterized by mild intellectual disability without consistent physical features. It has been described in boys with expanded cytosine-cytosine-guanine (CCG) repeats in fragile X mental retardation 2 (FMR2) gene, near the FMR1 gene.
•XXY (Klinefelter syndrome) – Boys with Klinefelter syndrome may have specific learning disabilities, particularly in expressive language. In contrast to postpubertal boys with FXS, boys with XXY usually have small testes. (See "The child with tall stature and/or abnormally rapid growth", section on 'Klinefelter syndrome'.)
•Cerebral gigantism (also known as Sotos syndrome) – Characteristic features of cerebral gigantism include typical facial appearance (macrocephaly, frontal bossing, prominent chin, pointed chin, downslanting palpebral fissures), overgrowth, learning disability, behavioral problems, and congenital cardiac anomalies. (See "The child with tall stature and/or abnormally rapid growth", section on 'Cerebral gigantism'.)
•Prader-Willi syndrome (PWS) – Some boys with FXS have a phenotype similar to that of PWS, but they do not have the genetic abnormalities associated with PWS. (See "Clinical features, diagnosis, and treatment of Prader-Willi syndrome" and 'Prader-Willi phenotype' above.)
RESOURCES — FXS resources for health care providers and families include:
●The National Fragile X Foundation
●The National Institute of Child Health and Human Development
●Genetic Testing Registry (GTR)
SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Fragile X syndrome".)
INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
●Basics topic (see "Patient education: Fragile X syndrome (The Basics)")
SUMMARY
●Fragile X syndrome (FXS) is the most frequent form of inherited intellectual disability, with a prevalence between 1 in 4000 and 1 in 7000 in males. The prevalence in females is approximately two-thirds to one-half of that in males. (See 'Epidemiology' above.)
●FXS is an X-linked disorder. It is caused by a loss-of-function mutation in the fragile X mental retardation 1 (FMR1) gene that leads to decreased or absent fragile X mental retardation protein (FMRP). (See 'Pathogenesis' above.)
●The clinical features of FXS vary depending upon the mutation state (full mutation versus premutation), degree of methylation, sex, and tissue variation (table 1). (See 'Clinical features' above.)
●All males with full-mutation FXS have manifestations of FXS, but there are a wide range of physical, cognitive, and behavioral features. (See 'Full mutation in boys' above.)
•Classic physical features include long and narrow face with prominent forehead and chin, large ears, and testicular enlargement, but these features typically are not obvious until adolescence or adulthood (picture 1). Physical features in younger males may include macrocephaly, strabismus, midface hypoplasia, arched palate, mitral valve prolapse, hyperextensible joints, hypotonia, soft skin, and flexible, flat feet.
•Intellectual disability is usually in the moderate range. Expressive language is more affected than receptive language.
•Behavioral features may include hyperactivity, inattention, gaze aversion, stereotypic movements (eg, hand flapping, hand biting), hyperarousal, social anxiety, and unusual speech.
●Girls with the full mutation usually have milder features than boys, and 50 percent have normal cognitive function. However, the full spectrum of cognitive, behavioral, and physical findings may occur. (See 'Full mutation in girls' above.)
●In the absence of a family history of FXS, diagnosis of FXS requires a low threshold for clinical suspicion based upon cognitive, developmental, or behavioral concerns, as described above. Diagnosis is confirmed by molecular testing. (See 'Diagnosis' above.)
●The differential diagnosis of FXS includes autism spectrum disorder, attention deficit hyperactivity disorder (ADHD), and other causes of intellectual disability or developmental delay. (See 'Differential diagnosis' above.)
ACKNOWLEDGMENT — We are saddened by the death of Carolyn Bridgemohan, MD, who passed away in August 2019. UpToDate wishes to acknowledge Dr. Bridgemohan's work as a Section Editor for Developmental and Behavioral Pediatrics.
1 : Prevalence of fragile X syndrome.
2 : Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.
3 : Advances in understanding fragile X syndrome and related disorders.
4 : Advances in understanding fragile X syndrome and related disorders.
5 : Advances in the treatment of fragile X syndrome.
6 : A point mutation in the FMR-1 gene associated with fragile X mental retardation.
7 : Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: a case report and review of the literature.
8 : Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles.
9 : Fragile X full mutation expansions are inhibited by one or more AGG interruptions in premutation carriers.
10 : The role of AGG interruptions in fragile X repeat expansions: a twenty-year perspective.
11 : Fragile X full mutation alleles composed of few alleles: implications for CGG repeat expansion.
12 : Fragile X syndrome.
13 : Epidemiology of fragile X syndrome: a systematic review and meta-analysis.
14 : Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group.
15 : Prevalence of carriers of premutation-size alleles of the FMRI gene--and implications for the population genetics of the fragile X syndrome.
16 : Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors.
17 : Evidence that methylation of the FMR-I locus is responsible for variable phenotypic expression of the fragile X syndrome.
18 : Molecular-clinical correlations in males with an expanded FMR1 mutation.
19 : A controlled study of longitudinal IQ changes in females and males with fragile X syndrome.
20 : Fragile X syndrome: an update and review for the primary pediatrician.
21 : Fragile X syndrome: an update and review for the primary pediatrician.
22 : The fragile X syndrome. A study of 83 families.
23 : Physical characteristics of young boys with fragile X syndrome: reasons for difficulties in making a diagnosis in young males.
24 : Standards for selected anthropometric measurements in males with the fragile X syndrome.
25 : Inherited congenital normofunctional testicular hyperplasia and mental deficiency.
26 : Inherited congenital normofunctional testicular hyperplasia and mental deficiency. A corroborative study.
27 : Fragile X syndrome.
28 : Consideration of connective tissue dysfunction in the fragile X syndrome.
29 : Orthopaedic aspects of fragile-X syndrome.
30 : Do young boys with fragile X syndrome have macroorchidism?
31 : Neuroanatomy of fragile X syndrome: the posterior fossa.
32 : The neuroanatomy and neuroendocrinology of fragile X syndrome.
33 : Neurodevelopmental effects of the FMR-1 full mutation in humans.
34 : Early development in males with Fragile X syndrome: a review of the literature.
35 : Fragile X syndrome: assessment and treatment implications.
36 : Fragile X boys: evolution of the mental age in childhood. Preliminary data on 10 prepubertal boys.
37 : Longitudinal study of cognitive abilities and adaptive behavior levels in fragile X males: a prospective multicenter analysis.
38 : Longitudinal profiles of adaptive behavior in fragile X syndrome.
39 : Mapping nonverbal IQ in young boys with fragile X syndrome.
40 : Receptive and expressive communication development of young males with fragile X syndrome.
41 : Conversational characteristics of children with fragile X syndrome: tangential language.
42 : Fragile (X) syndrome: a study of the psychological profile in 23 prepubertal patients.
43 : Cognitive profiles of boys with the fragile X syndrome.
44 : Cognitive profiles associated with the fra(X) syndrome in males and females.
45 : Executive Function in Fragile X Syndrome: A Systematic Review.
46 : Early behavior signs of psychiatric phenotypes in fragile X syndrome.
47 : Autism spectrum disorder in Fragile X syndrome: differential contribution of adaptive socialization and social withdrawal.
48 : Specification of the neurobehavioral phenotype in males with fragile X syndrome.
49 : Behavioral phenotype of fragile X syndrome: DSM-III-R autistic behavior in male children.
50 : Fragile X syndrome.
51 : Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.
52 : Psychopharmacology in fragile X syndrome--present and future.
53 : Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors.
54 : Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors.
55 : Autistic behavior in young boys with fragile X syndrome.
56 : Linguistic and cognitive functioning and autism symptoms in young children with fragile X syndrome.
57 : Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.
58 : ASD Comorbidity in Fragile X Syndrome: Symptom Profile and Predictors of Symptom Severity in Adolescent and Young Adult Males.
59 : Origins of epilepsy in fragile X syndrome.
60 : Epilepsy in fragile X syndrome.
61 : Epilepsy and EEG findings in males with fragile X syndrome.
62 : A peculiar subphenotype in the fra(X) syndrome: extreme obesity-short stature-stubby hands and feet-diffuse hyperpigmentation. Further evidence of disturbed hypothalamic function in the fra(X) syndrome?
63 : Clinical and molecular studies in fragile X patients with a Prader-Willi-like phenotype.
64 : Prader-Willi-like phenotype in fragile X syndrome.
65 : The Prader-Willi phenotype of fragile X syndrome.
66 : Girls with fragile X syndrome: physical and neurocognitive status and outcome.
67 : Neuropsychological profiles of FMR-1 premutation and full-mutation carrier females
68 : Profile of cognitive functioning in women with the fragile X mutation.
69 : Mental status of females with an FMR1 gene full mutation.
70 : Twin sisters, monozygotic with the fragile X mutation, but with a different phenotype.
71 : Psychiatric disorders associated with fragile X in the young female.
72 : Fragile X syndrome and selective mutism.
73 : A developmental approach to understanding Fragile X syndrome in females.
74 : Mental impairment in cytogenetically positive fragile X females.
75 : Psychiatric disability in female carriers of the fragile X chromosome.
76 : Autistic behaviors among girls with fragile X syndrome.
77 : Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families.
78 : Clinical involvement and protein expression in individuals with the FMR1 premutation.
79 : Clinical features of boys with fragile X premutations and intermediate alleles.
80 : Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.
81 : Neurobehavioural evidence for the involvement of the FMR1 gene in female carriers of fragile X syndrome.
82 : Fragile X spectrum disorders.
83 : Delayed diagnosis of fragile X syndrome--United States, 1990-1999.
84 : No change in the age of diagnosis for fragile x syndrome: findings from a national parent survey.
85 : Health supervision for children with fragile X syndrome.
86 : Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation.
87 : Fragile X syndrome: diagnostic and carrier testing.
88 : Fragile X syndrome: diagnostic and carrier testing.
89 : Clinical consult: developmental delay/fragile X syndrome.